We are pleased to announce that the 1st Collaborative Assessment of WP4 AC-B on “Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk” is ready now available.
Sudden cardiac arrest (SCA) is the most common cause of death in patients with coronary artery disease. Mostly, ventricular tachycardia and ventricular fibrillation are the underlying aetiology of SCA, which is claimed to be successfully treated by a novel defibrillation therapy, a wearable cardioverter defibrillator (WCD).
The assessment aimed to provide valid data on clinical effectiveness and safety of the WCD. Comparators were chosen based on CE mark indications, recommendations from relevant published clinical guidelines and according to the EUnetHTA guidelines. Furthermore, the project intended to elicit patients’ views on aspects regarding their cardiac disease and the WCD therapy as well as to identify neglected outcomes.
The collaborative assessment can be found here.
